Nicotine bitartrate reduces falls and freezing of gait in Parkinson disease: A reanalysis

Abraham Lieberman, Thurmon Lockhart, Markey C. Olson, Victoria A. Smith Hussain, Christopher W. Frames, Arshia Sadreddin, Margaret McCauley, Elizabeth Ludington

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: Determine if NC001, an oral formulation of nicotine that reduces levodopa-induced dyskinesias (LIDs) in MPTP-Parkinson monkeys, could reduce falls, freezing of gait (FOG), and LIDs in Parkinson disease (PD) patients. Methods: Previously collected data from a study analyzing the effects of NC001 on LIDs in PD patients were reanalyzed. Because indirect-acting cholinergic drugs are sometimes helpful in reducing falls, we hypothesized that NC001, a direct-acting cholinergic agonist, could reduce falls in PD. The original 12-center, double-blind, randomized trial enrolled 65 PD patients. NC001 or placebo was administered 4 times per day for 10 weeks, beginning at 4 mg/day and escalating to 24 mg/day. Assessments included the Unified Dyskinesia Rating Scale (UDysRS) and Parts II-III of the original Unified Parkinson's Disease Rating Scale (UPDRS). Results: Randomization (1:1) resulted in 35 patients on NC001 and 30 on placebo at baseline. Thirty and 27 patients, respectively, had data available for an intent-to-treat analysis. NC001 was safe and well-tolerated. After 10 weeks, NC001 patients (14/30) had a significant reduction in falls vs. placebo patients (3/27) (p = 0.0041) as assessed by UPDRS Part II. NC001 patients (12/30) also had significantly reduced FOG vs. placebo patients (4/27) (p = 0.0043). NC001 patients, compared with placebo patients, had a significant improvement (p = 0.01) in UDysRS ambulation subtest (40% vs. 3%, respectively). Although NC001 patients had a greater reduction in dyskinesias on the UDysRS than placebo patients (30% vs. 19%, respectively), this was not significant (p = 0.09). Conclusions: NC001 significantly improved two refractory symptoms of PD, falls and FOG. The reduction in falls and FOG is attributed to selective stimulation of nicotinic receptors.

Original languageEnglish (US)
Article number424
JournalFrontiers in Neurology
Volume10
Issue numberMAY
DOIs
StatePublished - Jan 1 2019

Fingerprint

Nicotine
Gait
Freezing
Parkinson Disease
Dyskinesias
Placebos
Levodopa
Cholinergic Agonists
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Nicotinic Receptors
Random Allocation
Cholinergic Agents
Walking
Haplorhini

Keywords

  • Dyskinesia
  • Falls
  • Freezing of gait
  • Nicotine
  • Parkinson disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Lieberman, A., Lockhart, T., Olson, M. C., Smith Hussain, V. A., Frames, C. W., Sadreddin, A., ... Ludington, E. (2019). Nicotine bitartrate reduces falls and freezing of gait in Parkinson disease: A reanalysis. Frontiers in Neurology, 10(MAY), [424]. https://doi.org/10.3389/fneur.2019.00424

Nicotine bitartrate reduces falls and freezing of gait in Parkinson disease : A reanalysis. / Lieberman, Abraham; Lockhart, Thurmon; Olson, Markey C.; Smith Hussain, Victoria A.; Frames, Christopher W.; Sadreddin, Arshia; McCauley, Margaret; Ludington, Elizabeth.

In: Frontiers in Neurology, Vol. 10, No. MAY, 424, 01.01.2019.

Research output: Contribution to journalArticle

Lieberman, A, Lockhart, T, Olson, MC, Smith Hussain, VA, Frames, CW, Sadreddin, A, McCauley, M & Ludington, E 2019, 'Nicotine bitartrate reduces falls and freezing of gait in Parkinson disease: A reanalysis', Frontiers in Neurology, vol. 10, no. MAY, 424. https://doi.org/10.3389/fneur.2019.00424
Lieberman, Abraham ; Lockhart, Thurmon ; Olson, Markey C. ; Smith Hussain, Victoria A. ; Frames, Christopher W. ; Sadreddin, Arshia ; McCauley, Margaret ; Ludington, Elizabeth. / Nicotine bitartrate reduces falls and freezing of gait in Parkinson disease : A reanalysis. In: Frontiers in Neurology. 2019 ; Vol. 10, No. MAY.
@article{5e9f2abff121494eadebc01bdb070889,
title = "Nicotine bitartrate reduces falls and freezing of gait in Parkinson disease: A reanalysis",
abstract = "Objective: Determine if NC001, an oral formulation of nicotine that reduces levodopa-induced dyskinesias (LIDs) in MPTP-Parkinson monkeys, could reduce falls, freezing of gait (FOG), and LIDs in Parkinson disease (PD) patients. Methods: Previously collected data from a study analyzing the effects of NC001 on LIDs in PD patients were reanalyzed. Because indirect-acting cholinergic drugs are sometimes helpful in reducing falls, we hypothesized that NC001, a direct-acting cholinergic agonist, could reduce falls in PD. The original 12-center, double-blind, randomized trial enrolled 65 PD patients. NC001 or placebo was administered 4 times per day for 10 weeks, beginning at 4 mg/day and escalating to 24 mg/day. Assessments included the Unified Dyskinesia Rating Scale (UDysRS) and Parts II-III of the original Unified Parkinson's Disease Rating Scale (UPDRS). Results: Randomization (1:1) resulted in 35 patients on NC001 and 30 on placebo at baseline. Thirty and 27 patients, respectively, had data available for an intent-to-treat analysis. NC001 was safe and well-tolerated. After 10 weeks, NC001 patients (14/30) had a significant reduction in falls vs. placebo patients (3/27) (p = 0.0041) as assessed by UPDRS Part II. NC001 patients (12/30) also had significantly reduced FOG vs. placebo patients (4/27) (p = 0.0043). NC001 patients, compared with placebo patients, had a significant improvement (p = 0.01) in UDysRS ambulation subtest (40{\%} vs. 3{\%}, respectively). Although NC001 patients had a greater reduction in dyskinesias on the UDysRS than placebo patients (30{\%} vs. 19{\%}, respectively), this was not significant (p = 0.09). Conclusions: NC001 significantly improved two refractory symptoms of PD, falls and FOG. The reduction in falls and FOG is attributed to selective stimulation of nicotinic receptors.",
keywords = "Dyskinesia, Falls, Freezing of gait, Nicotine, Parkinson disease",
author = "Abraham Lieberman and Thurmon Lockhart and Olson, {Markey C.} and {Smith Hussain}, {Victoria A.} and Frames, {Christopher W.} and Arshia Sadreddin and Margaret McCauley and Elizabeth Ludington",
year = "2019",
month = "1",
day = "1",
doi = "10.3389/fneur.2019.00424",
language = "English (US)",
volume = "10",
journal = "Frontiers in Neurology",
issn = "1664-2295",
publisher = "Frontiers Research Foundation",
number = "MAY",

}

TY - JOUR

T1 - Nicotine bitartrate reduces falls and freezing of gait in Parkinson disease

T2 - A reanalysis

AU - Lieberman, Abraham

AU - Lockhart, Thurmon

AU - Olson, Markey C.

AU - Smith Hussain, Victoria A.

AU - Frames, Christopher W.

AU - Sadreddin, Arshia

AU - McCauley, Margaret

AU - Ludington, Elizabeth

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: Determine if NC001, an oral formulation of nicotine that reduces levodopa-induced dyskinesias (LIDs) in MPTP-Parkinson monkeys, could reduce falls, freezing of gait (FOG), and LIDs in Parkinson disease (PD) patients. Methods: Previously collected data from a study analyzing the effects of NC001 on LIDs in PD patients were reanalyzed. Because indirect-acting cholinergic drugs are sometimes helpful in reducing falls, we hypothesized that NC001, a direct-acting cholinergic agonist, could reduce falls in PD. The original 12-center, double-blind, randomized trial enrolled 65 PD patients. NC001 or placebo was administered 4 times per day for 10 weeks, beginning at 4 mg/day and escalating to 24 mg/day. Assessments included the Unified Dyskinesia Rating Scale (UDysRS) and Parts II-III of the original Unified Parkinson's Disease Rating Scale (UPDRS). Results: Randomization (1:1) resulted in 35 patients on NC001 and 30 on placebo at baseline. Thirty and 27 patients, respectively, had data available for an intent-to-treat analysis. NC001 was safe and well-tolerated. After 10 weeks, NC001 patients (14/30) had a significant reduction in falls vs. placebo patients (3/27) (p = 0.0041) as assessed by UPDRS Part II. NC001 patients (12/30) also had significantly reduced FOG vs. placebo patients (4/27) (p = 0.0043). NC001 patients, compared with placebo patients, had a significant improvement (p = 0.01) in UDysRS ambulation subtest (40% vs. 3%, respectively). Although NC001 patients had a greater reduction in dyskinesias on the UDysRS than placebo patients (30% vs. 19%, respectively), this was not significant (p = 0.09). Conclusions: NC001 significantly improved two refractory symptoms of PD, falls and FOG. The reduction in falls and FOG is attributed to selective stimulation of nicotinic receptors.

AB - Objective: Determine if NC001, an oral formulation of nicotine that reduces levodopa-induced dyskinesias (LIDs) in MPTP-Parkinson monkeys, could reduce falls, freezing of gait (FOG), and LIDs in Parkinson disease (PD) patients. Methods: Previously collected data from a study analyzing the effects of NC001 on LIDs in PD patients were reanalyzed. Because indirect-acting cholinergic drugs are sometimes helpful in reducing falls, we hypothesized that NC001, a direct-acting cholinergic agonist, could reduce falls in PD. The original 12-center, double-blind, randomized trial enrolled 65 PD patients. NC001 or placebo was administered 4 times per day for 10 weeks, beginning at 4 mg/day and escalating to 24 mg/day. Assessments included the Unified Dyskinesia Rating Scale (UDysRS) and Parts II-III of the original Unified Parkinson's Disease Rating Scale (UPDRS). Results: Randomization (1:1) resulted in 35 patients on NC001 and 30 on placebo at baseline. Thirty and 27 patients, respectively, had data available for an intent-to-treat analysis. NC001 was safe and well-tolerated. After 10 weeks, NC001 patients (14/30) had a significant reduction in falls vs. placebo patients (3/27) (p = 0.0041) as assessed by UPDRS Part II. NC001 patients (12/30) also had significantly reduced FOG vs. placebo patients (4/27) (p = 0.0043). NC001 patients, compared with placebo patients, had a significant improvement (p = 0.01) in UDysRS ambulation subtest (40% vs. 3%, respectively). Although NC001 patients had a greater reduction in dyskinesias on the UDysRS than placebo patients (30% vs. 19%, respectively), this was not significant (p = 0.09). Conclusions: NC001 significantly improved two refractory symptoms of PD, falls and FOG. The reduction in falls and FOG is attributed to selective stimulation of nicotinic receptors.

KW - Dyskinesia

KW - Falls

KW - Freezing of gait

KW - Nicotine

KW - Parkinson disease

UR - http://www.scopus.com/inward/record.url?scp=85068026608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068026608&partnerID=8YFLogxK

U2 - 10.3389/fneur.2019.00424

DO - 10.3389/fneur.2019.00424

M3 - Article

AN - SCOPUS:85068026608

VL - 10

JO - Frontiers in Neurology

JF - Frontiers in Neurology

SN - 1664-2295

IS - MAY

M1 - 424

ER -